[email protected] This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
However, not everyone produces sufficient levels of GLP-1, especially those who struggle with obesity or type 2 diabetes
Supporting appetite control (helping to reduce calories in) and increased metabolism and calorie burn (expediting calories out) are just two of the key reasons to add this to your daily routine
Studies utilizing Alzheimers disease models suggest that semaglutide treatment inhibits the activation of microglia and astrocytes, thereby reducing the release of pro-inflammatory mediators ( 5.2 Enhanced brain metabolism and insulin sensitivity The association between Alzheimers disease (AD) and metabolic dysfunction has led to the characterization of AD as Type 3 diabetes, a condition marked by impaired insulin signaling and glucose utilization in the brain ( 5.3 Direct neuroprotective and pro-survival pathways In addition to its anti-inflammatory and metabolic effects, semaglutide activates pathways that directly enhance neuronal survival and resilience
This makes it part of a unique class of peptides called mitochondrial-derived peptides (MDPs) small proteins that act as signaling molecules to regulate metabolism and cellular stress responses
Abbreviations: BMI body mass index CI confidence interval CVD cardiovascular disease GLP-1 glucagon-like peptide-1 GLP-1 RA glucagon-like peptide-1 receptor agonist I 2 = inconsistency index OR odds ratio RCT randomized controlled trial SUCRA surface under the cumulative ranking curve T2D type 2 diabetes The authors extend their appreciation to Prince Sattam bin Abdulaziz University for funding this research work through the project number (PSAU/2024/03/25233)
